Tag:
Onglyza
Latest Headlines
Latest Headlines
Safety watchdog flags GLP-1 drugs for pancreatitis reports to FDA
A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.
Drugmakers beware, Costco now in pharmacy benefits
In the evolving drug payer world, pharmacy benefit managers (PBM) are commanding a bigger role. Now drug companies have a new and interesting PBM with which to contend--Costco.
Bristol, AstraZeneca chalk up EU approval for Forxiga after FDA rejection
Once again, European regulators have shown that they don't always see eye-to-eye with the their counterparts in the U.S. The European Commission welcomed a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, dubbed Forxiga, just months after FDA rejected it on safety worries.
Generics drag AZ sales down by $1.35B
AstraZeneca's second-quarter results continue the generics-are-woe trend in Big Pharma. This time, it's the antipsychotic drug Seroquel doing most of the damage.
Bristol stays in hunt for Amylin
After Amylin reportedly declined BMS' recent buyout offer, Bristol isn't giving up on its plans to gobble up the diabetes drugmaker, The Wall Street Journal reported.
Bristol-Myers' Q4 shows growth in newer products
Bristol-Myers Squibb's ( $BMY ) earnings didn't reach the Wall Street goalposts, partly because of higher costs, some of them attributed to U.S. healthcare reforms. Sales of its flagship drug,...
EMA gives nod to AZ/BMS diabetes pill
Drugmakers got some good news from the European Medicines Agency today. AstraZeneca ( $AZ ) and Bristol-Myers Squibb ( $BMY ) garnered a positive opinion from the EMA on the companies' bid to gain
If Avandia falls, which diabetes meds fill the gap?
We won't have an indication of Avandia 's future until this afternoon's advisory panel vote. And we won't know for sure until FDA itself makes its decision. But analysts tend to think that if Avandia
Will new blockbusters follow a new model?
Should pharma-watchers be worried about Eli Lilly and Bristol-Myers Squibb? After all, they both launched blockbuster hopefuls--the clot-buster Effient for Lilly, the diabetes remedy Onglyza for
Januvia gets head-to-head rival in Onglyza
Watch out, Januvia . AstraZeneca and Bristol-Myers Squibb finally won FDA approval for their diabetes drug Onglyza, a DPP-4 inhibitor that will directly compete with Merck's fast-growing treatment.
